BridgeBio Pharma, Inc. (BBIO) FinancialsBBIOFinancialBridgeBio Pharma, Inc.

Evaluating the bottom line, BridgeBio Pharma, Inc. maintains a gross margin of 93.83%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -43.94%, while the net margin is -63.97%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively BBIO converts its operational activities into shareholder value.

In the context of the broader market, BBIO competes directly with industry leaders such as NBIX and BMRN. With a market capitalization of $15.38B, it holds a significant position in the sector. When comparing efficiency, BBIO's gross margin of 93.83% stands against NBIX's 95.87% and BMRN's 72.08%. Such benchmarking helps identify whether BridgeBio Pharma, Inc. is trading at a premium or discount relative to its financial performance.

BridgeBio reported total revenue of 243.7 million USD in Q2 2026, driven primarily by its Attruby drug, which saw sales triple year-over-year to over 222 million USD. However, the company continues to report significant net losses, with a net income of -152.2 million USD in the same quarter.